Donepezil

Drug Profile

Donepezil

Alternative Names: Aricept; Aricept D; Aricept Dry Syrup; Aricept Evess; Aricept ODT; Aricept SR; Donepezil hydrochloride; Donepezil SR; E 2020; E 2022; Eranz

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; ICURE; Pfizer; Teikoku Pharma USA
  • Class Antidementias; Indans; Nootropics; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Lewy body disease; Vascular dementia
  • Phase III Down syndrome
  • No development reported Attention deficit and disruptive behaviour disorders; Migraine
  • Discontinued Aphasia; Attention-deficit hyperactivity disorder; Dementia; Mild cognitive impairment

Most Recent Events

  • 30 Jun 2017 Icure Pharmaceutical plans a phase III trial for Alzheimer's disease in South Korea (NCT03197740)
  • 21 Apr 2017 Eisai completes a phase II trial in Down syndrome in Japan (PO) (NCT02094053)
  • 09 Mar 2017 Eisai re-initiates enrolment in a phase III trial for Down syndrome (In children, In adolescents) in USA (EudraCT2016-004948-11)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top